Category Archives: Infectious Disease

Tygacil tigecycline Drug Safety Communication

Share

Tygacil (tigecycline): Drug Safety Communication – Increased Risk of Death AUDIENCE: Infectious Disease, Critical Care, Pharmacy ISSUE: FDA notified health professionals and their medical care organizations of a new Boxed Warning describing an increased risk  of death when intravenous Tygacil … Continue reading

Share
Posted in Critical Care Medicine, FDA 2013, FDA Safety Communication, Infectious Disease, Pharmacy | Tagged , , , , , , , , , | Comments Off on Tygacil tigecycline Drug Safety Communication

Fluoroquinolone Antibacterial Drugs Drug Safety Communication

Share

Fluoroquinolone Antibacterial Drugs: Drug Safety Communication- Risk for possibly permanent nerve damage AUDIENCE: Family Practice, Infectious Disease, Pharmacy ISSUE: FDA has required the drug labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious … Continue reading

Share
Posted in Family Practice, FDA 2013, FDA Safety Communication, Infectious Disease, Pharmacy | Tagged , , , , , , | Comments Off on Fluoroquinolone Antibacterial Drugs Drug Safety Communication

Mefloquine Hydrochloride Drug Safety Communication

Share

Mefloquine Hydrochloride: Drug Safety Communication – Label Changes Due To Risk of Serious Psychiatric and Nerve Side Effects AUDIENCE: Infectious Disease, Emergency Medicine, Psychiatry, Pharmacy, Patient ISSUE: FDA is advising the public about strengthened and updated warnings regarding neurologic and … Continue reading

Share
Posted in Emergency Rooms, FDA 2013, FDA Safety Communication, Infectious Disease, Patients, Pharmacy, Psychiatry | Tagged , , , , , , , , , , , | Comments Off on Mefloquine Hydrochloride Drug Safety Communication

Nizoral ketoconazole Drug Safety Communication

Share

Nizoral (ketoconazole): Drug Safety Communication – Potentially Fatal Liver Injury, Risk of Drug Interactions and Adrenal Gland Problems AUDIENCE: Internal Medicine, Infectious Disease ISSUE: FDA is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug’s use, … Continue reading

Share
Posted in FDA 2013, FDA Safety Communication, Infectious Disease, Internal Medicine | Tagged , , , , , , , , | Comments Off on Nizoral ketoconazole Drug Safety Communication

Medical Bed Mattresses FDA Safety Communication

Share

Medical Bed Mattresses: FDA Safety Communication – Damaged or Worn Covers Pose Risk of Contamination and Infection AUDIENCE: Biomedical Engineering, Infectious Disease, Nursing, Risk Managers ISSUE: From January 2011 to January 2013, the FDA received 458 reports associated with medical … Continue reading

Share
Posted in Biomedical Engineering, FDA 2013, FDA Label Change, FDA Safety Communication, Infectious Disease, Nursing, Risk Manager | Tagged , , , , , , , , , , | Comments Off on Medical Bed Mattresses FDA Safety Communication

BIVIGAM Immune Globulin Intravenous Recall

Share

BIVIGAM Immune Globulin Intravenous (Human), 10 Percent Liquid, 100 mL Sterile Vial: Recall – Visible Particles Observed AUDIENCE: Risk Manager, Infectious Disease, Health Professional ISSUE: During a routine annual reserve inspection, visible particles were observed in lot number 120016 (Expiration … Continue reading

Share
Posted in FDA 2013, FDA Recall, Healthcare Professionals, Infectious Disease, Risk Manager | Tagged , , , , , , , , , , , , , | Comments Off on BIVIGAM Immune Globulin Intravenous Recall

Cefepime Label Change drug risks

Share

Cefepime:Label Change- Risk of Seizure in Patients Not Receiving Dosage Adjustments for Kidney Impairment   Audience: Health Professional,Infectious Disease, Nephrology Issue: There have been cases of a specific type of seizure called nonconvulsive status epilepticus associated with the use of … Continue reading

Share
Posted in FDA 2012, FDA Warning, Healthcare Professionals, Infectious Disease, Nephrology | Tagged , , , , , , , , , , , | Comments Off on Cefepime Label Change drug risks

Victrelis drug label revised Drug Safety Communication

Share

Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication – Drug Interactions [UPDATED 04/26/2012] FDA notified healthcare professionals that the Victrelis drug label has been revised to state that co-administration of Victrelis (boceprevir), a hepatitis … Continue reading

Share
Posted in FDA 2012, FDA Label Change, FDA Safety Communication, Infectious Disease, Pharmacy | Tagged , , , , , , , , , | Comments Off on Victrelis drug label revised Drug Safety Communication

Generic Ultrasound Transmission Gel Safety Communication

Share

Other‐Sonic Generic Ultrasound Transmission Gel: Safety Communication – Risk of Bacterial Contamination AUDIENCE: Risk Manager, OB/GYN, Radiology, Infectious Disease ISSUE: FDA notified health care professionals and facilities to STOP using Other‐Sonic Generic Ultrasound Transmission Gel manufactured June though December 2011, … Continue reading

Share
Posted in FDA 2012, FDA Warning, Infectious Disease, OBGYN, Radiology, Risk Manager | Tagged , , , , , , , , | Comments Off on Generic Ultrasound Transmission Gel Safety Communication

Statins and HIV or Hepatitis C Drugs Drug Safety Communication

Share

Statins and HIV or Hepatitis C Drugs: Drug Safety Communication – Interaction Increases Risk of Muscle Injury AUDIENCE: Infectious Disease, Family Practice, Patients ISSUE: FDA notified healthcare professionals of updates to the prescribing information concerning interactions between  protease inhibitors and certain statin drugs. … Continue reading

Share
Posted in Family Practice, FDA 2012, FDA Safety Communication, Infectious Disease, Patients | Tagged , , , , , , , , , , , , | Comments Off on Statins and HIV or Hepatitis C Drugs Drug Safety Communication